Literature DB >> 2125213

An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells.

S A Rabbani1, J Desjardins, A W Bell, D Banville, A Mazar, J Henkin, D Goltzman.   

Abstract

A peptide mitogen for cultured osteoblast-like cells was purified from serum-free conditioned culture medium of a human prostatic cancer cell line, PC-3. Based on amino acid sequencing and estimated molecular weight, this peptide was identified as an NH2-terminal fragment of urokinase-type plasminogen activator (uPA). Recombinant high molecular weight (HMW) uPA and the NH2-terminal growth factor domain (GFD) of uPA, but not low molecular weight (LMW) uPA (lacking the NH2-terminal region) stimulated [3H] thymidine incorporation and proliferation in osteoblast-like cells, and specific, competitive binding sites for HMW, but not LMW, uPA were demonstrable. These studies demonstrate the production of a mitogenic NH2-terminal fragment of uPA by a human prostatic cancer cell line which may be of importance in the pathogenesis of osteoblastic metastases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2125213     DOI: 10.1016/s0006-291x(05)80893-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR.

Authors:  Gabriele Eden; Marco Archinti; Ralitsa Arnaudova; Giuseppina Andreotti; Andrea Motta; Federico Furlan; Valentina Citro; Maria Vittoria Cubellis; Bernard Degryse
Journal:  Cell Mol Life Sci       Date:  2017-11-28       Impact factor: 9.261

2.  Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton.

Authors:  C Reyes-Moreno; M Koutsilieris
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

Review 3.  Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management.

Authors:  Kosei Nakajima; Dong Hyo Kho; Takashi Yanagawa; Melissa Zimel; Elisabeth Heath; Victor Hogan; Avraham Raz
Journal:  Cancer Metastasis Rev       Date:  2016-06       Impact factor: 9.264

4.  Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.

Authors:  V Stepanova; S Mukhina; E Köhler; T J Resink; P Erne; V A Tkachuk
Journal:  Mol Cell Biochem       Date:  1999-05       Impact factor: 3.396

5.  Homing of cancer cells to the bone.

Authors:  Anjali Mishra; Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Cancer Microenviron       Date:  2011-08-09

Review 6.  Bone metastasis in prostate cancer: emerging therapeutic strategies.

Authors:  Justin Sturge; Matthew P Caley; Jonathan Waxman
Journal:  Nat Rev Clin Oncol       Date:  2011-05-10       Impact factor: 66.675

7.  Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment.

Authors:  D A Fishman; A Kearns; S Larsh; J J Enghild; M S Stack
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

Review 8.  Bone metabolism and new targets for intervention.

Authors:  Bulent Akduman; E David Crawford
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

9.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 10.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.